- E-therapeutics said Monday it had agreed a research collaboration with Novo Nordisk under which the companies would use e-therapeutics' proprietary Network-Driven Drug Discovery platform to look to discover potentially novel biological mechanisms and therapeutic approaches for a specific area of type-2 diabetes.

Under the agreement, e-therapeutics would work with Novo Nordisk over a period of 12 months, and use its Network-Driven Drug Discovery approach to 'identify novel intervention strategies, biological pathways and compounds for testing that could potentially form the basis of novel therapies, the company said.

'We are looking forward to cooperating with e-therapeutics. It is an exciting technology and we will investigate if it can support some of the early target discovery efforts we are building in Novo Nordisk Research Center Oxford,' said Jan Nygaard Jensen, Deputy Head of Novo Nordisk Research Center Oxford and Head of Bioinformatics.

At 8:20am: [LON:ETX] eTherapeutics PLC share price was 0p at 6.75p

Story provided by